A repurposed FDA-approved drug candidate, dubbed compound X, improved mobility in Parkinson’s-like mice by enhancing glymphatic brain waste clearance.
A repurposed drug candidate described only as “compound X” has shown encouraging effects in mice with Parkinson’s-like symptoms, pointing to a possible disease-modifying strategy rather than one that simply masks movement problems.
In work led by researchers at Swinburne University of Technology. the compound X approach targets a problem that sits upstream of many Parkinson’s symptoms: toxic clumps of alpha-synuclein protein.. Misryoum reports that the team’s central idea is to strengthen the brain’s “waste disposal” system—known as the glymphatic system—so that misfolded protein accumulations clear more effectively.
Parkinson’s disease affects more than 10 million people worldwide and is driven by the progressive loss of nerve cells involved in movement control.. A major feature of the disorder is the build-up of a misfolded form of alpha-synuclein. which forms clumps and disrupts neural function.. At the same time. several studies have linked Parkinson’s to impaired clearance pathways in the brain. including the glymphatic system. which is thought to move fluid through brain tissue and help remove unwanted molecules.
To test whether boosting glymphatic clearance could ease Parkinson’s-like symptoms. Misryoum explains that the researchers used a mouse model designed to better mimic key aspects of the human disease.. Rather than inducing symptoms through broad brain injury—something that can produce movement impairment without recreating the alpha-synuclein clumps seen in patients—the team repeatedly introduced drops containing misfolded alpha-synuclein into the animals’ noses.. Over time, the protein spreads through and around the brain, leading to worsening mobility.
The study involved 20 mice exposed to weekly doses of misfolded alpha-synuclein for four months.. Around the two-month mark—when symptoms were progressing but aligned with an early disease stage—half the mice began receiving compound X four times per week.. The drug is already approved by the US Food and Drug Administration. a detail that matters because it may shorten the path to human testing if safety translates.. To help delivery, the mice also received methylcellulose, a chemical used to improve how the drug dissolves.
The rest of the animals received methylcellulose only as controls.. The researchers then evaluated motor behavior using two tasks.. In a pole test. where the mice had to carefully turn and descend. 80% of the animals given compound X successfully completed the task. compared with just 10% of the control group.. In a separate balancing test on a rotating rod for five minutes. nearly all compound X-treated mice stayed on for the full interval. while control animals typically fell off after about three minutes.
Misryoum analysis suggests the most biologically telling findings came from what the compound did during sleep.. Further experiments indicated that compound X enhanced slow brainwaves during deep sleep.. Those slow waves are closely tied to glymphatic function. and in this model the improved brain fluid movement was associated with a reduction in alpha-synuclein clumps in the motor cortex—the region controlling movement.. Compared with controls, the average clump burden dropped by about 40%.
For clinicians and researchers. the concept is significant because the current standard of care in Parkinson’s often improves symptoms without necessarily slowing the underlying neurodegenerative process.. A researcher not affiliated with the drug work. Misryoum notes. emphasized that there is an unmet need for therapies that can delay or slow disease progression.. Treatments that temporarily relieve movement issues can still be valuable. but they don’t always change what the disease is doing biologically day to day.
Why might improving sleep-linked clearance pathways matter so much?. Parkinson’s progresses slowly. and protein handling inside the brain is not a one-time event; it is a daily balance between production. misfolding. and clearance.. The glymphatic system is thought to be most active during certain sleep phases, particularly deep sleep.. By increasing slow-wave activity. compound X may be nudging the brain toward a more efficient cleanup rhythm—making it harder for harmful alpha-synuclein to accumulate and seed further pathology.
The team’s next step is straightforward in concept but difficult in practice: moving from animal outcomes to human evidence.. They hope to seek regulatory permission to begin trials in people with early-stage Parkinson’s within the next year. Misryoum reports.. Their long-term goal is to treat at the earliest phase. when the most benefit could come from preventing or slowing the cascade of protein aggregation and brain dysfunction.
If these results hold up. compound X could become an early signal of what many in the field are searching for: a strategy that changes disease trajectory rather than only easing symptoms.. The next chapter will depend on whether enhanced glymphatic clearance and reduced alpha-synuclein burden can be demonstrated safely and meaningfully in humans—and whether the biological mechanism translates into lasting clinical benefit.